Literature DB >> 34850740

SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?

Justin B Echouffo-Tcheugui1, Sabra C Lewsey2, Robert G Weiss2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34850740      PMCID： PMC8631587          DOI： 10.1172/JCI156309

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  21 in total

1.  Fatigability, Exercise Intolerance, and Abnormal Skeletal Muscle Energetics in Heart Failure.

Authors:  Kilian Weiss; Michael Schär; Gurusher S Panjrath; Yi Zhang; Kavita Sharma; Paul A Bottomley; Asieh Golozar; Angela Steinberg; Gary Gerstenblith; Stuart D Russell; Robert G Weiss
Journal:  Circ Heart Fail       Date:  2017-07       Impact factor: 8.790

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

3.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

Authors:  Stefan D Anker; Javed Butler; Gerasimos Filippatos; João P Ferreira; Edimar Bocchi; Michael Böhm; Hans-Peter Brunner-La Rocca; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure-Valenzuela; Nadia Giannetti; Juan Esteban Gomez-Mesa; Stefan Janssens; James L Januzzi; Jose R Gonzalez-Juanatey; Bela Merkely; Stephen J Nicholls; Sergio V Perrone; Ileana L Piña; Piotr Ponikowski; Michele Senni; David Sim; Jindrich Spinar; Iain Squire; Stefano Taddei; Hiroyuki Tsutsui; Subodh Verma; Dragos Vinereanu; Jian Zhang; Peter Carson; Carolyn Su Ping Lam; Nikolaus Marx; Cordula Zeller; Naveed Sattar; Waheed Jamal; Sven Schnaidt; Janet M Schnee; Martina Brueckmann; Stuart J Pocock; Faiez Zannad; Milton Packer
Journal:  N Engl J Med       Date:  2021-08-27       Impact factor: 176.079

4.  Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.

Authors:  Chiara Ghezzi; Amy S Yu; Bruce A Hirayama; Vladimir Kepe; Jie Liu; Claudio Scafoglio; David R Powell; Sung-Cheng Huang; Nagichettiar Satyamurthy; Jorge R Barrio; Ernest M Wright
Journal:  J Am Soc Nephrol       Date:  2016-09-12       Impact factor: 10.121

5.  Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure.

Authors:  Kenneth C Bedi; Nathaniel W Snyder; Jeffrey Brandimarto; Moez Aziz; Clementina Mesaros; Andrew J Worth; Linda L Wang; Ali Javaheri; Ian A Blair; Kenneth B Margulies; J Eduardo Rame
Journal:  Circulation       Date:  2016-01-27       Impact factor: 29.690

Review 6.  Unlocking the Secrets of Mitochondria in the Cardiovascular System: Path to a Cure in Heart Failure—A Report from the 2018 National Heart, Lung, and Blood Institute Workshop

Authors:  Rong Tian; Wilson S. Colucci; Zoltan Arany; Markus M. Bachschmid; Scott W. Ballinger; Sihem Boudina; James E. Bruce; David W. Busija; Sergey Dikalov; Gerald W. Dorn; Zorina S. Galis; Roberta A. Gottlieb; Daniel P. Kelly; Richard N. Kitsis; Mark J. Kohr; Daniel Levy; E. Douglas Lewandowski; Joseph M. McClung; Daria Mochly-Rosen; Kevin D. O'Brien; Brian O'Rourke; Joon-Young Park; Peipei Ping; Michael N. Sack; Shey-Shing Sheu; Yang Shi; Sruti Shiva; Douglas C. Wallace; Robert G. Weiss; Hilary J. Vernon; Renee Wong; Lisa Schwartz Longacre
Journal:  Circulation       Date:  2019-10-01       Impact factor: 29.690

7.  Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.

Authors:  Hao Zhou; Shuyi Wang; Pingjun Zhu; Shunying Hu; Yundai Chen; Jun Ren
Journal:  Redox Biol       Date:  2017-12-30       Impact factor: 11.799

Review 8.  Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review.

Authors:  Gary D Lopaschuk; Subodh Verma
Journal:  JACC Basic Transl Sci       Date:  2020-06-22

9.  Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.

Authors:  Masashi Mizuno; Atsushi Kuno; Toshiyuki Yano; Takayuki Miki; Hiroto Oshima; Tatsuya Sato; Kei Nakata; Yukishige Kimura; Masaya Tanno; Tetsuji Miura
Journal:  Physiol Rep       Date:  2018-06

Review 10.  SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?

Authors:  Steffen Pabel; Nazha Hamdani; Mark Luedde; Samuel Sossalla
Journal:  Curr Heart Fail Rep       Date:  2021-09-15
View more
  1 in total

1.  Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF).

Authors:  María Valero-Muñoz; Eng Leng Saw; Ryan M Hekman; Benjamin C Blum; Zaynab Hourani; Henk Granzier; Andrew Emili; Flora Sam
Journal:  Front Cardiovasc Med       Date:  2022-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.